Second-Degree Heart Block on ECG

Introduction

Second-degree heart block is a type of atrioventricular (AV) block where some electrical signals from the atria fail to reach the ventricles. This results in dropped heartbeats and can lead to dizziness, fainting, or more severe arrhythmias.

There are two types of second-degree heart block:

  1. Mobitz Type I (Wenckebach)
  2. Mobitz Type II

Mobitz Type I (Wenckebach)

ECG Features:

  • Progressive prolongation of the PR interval until a QRS complex is dropped.
  • After the dropped beat, the cycle repeats itself.
  • Usually benign and may not require treatment unless symptomatic.

Causes:

  • High vagal tone (common in athletes)
  • Medications (beta-blockers, calcium channel blockers, digoxin)
  • Inferior myocardial infarction

Mobitz Type II

ECG Features:

  • PR interval remains constant, but intermittent QRS complexes are missing.
  • More dangerous because it can progress to complete heart block (third-degree AV block).

Causes:

  • Structural heart disease (e.g., fibrosis of the conduction system)
  • Myocardial infarction (especially anterior MI)
  • Drug toxicity

Diagnosis and Treatment

  • ECG is the main diagnostic tool.
  • Mobitz I may not need treatment unless symptomatic; if needed, atropine or pacemaker implantation may be considered.
  • Mobitz II often requires a pacemaker, as it poses a higher risk of progressing to a complete heart block.

Conclusion

Identifying second-degree AV block on ECG is crucial to determining the need for intervention. Mobitz Type I is generally benign, while Mobitz Type II often requires immediate attention to prevent complications.

Source recommendations

1. American Heart Association – 2023 AHA/ACC/HRS Guideline for the Evaluation and Management of Patients With Cardiac Conduction Disorders

  1. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193
  2. https://www.heartrhythmjournal.com/article/S1547-5271(23)02026-X/fulltext
  3. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000628
  4. https://professional.heart.org/en/science-news/periprocedural-management-and-multidisciplinary-care-pathways-for-patients-with-cardiac-implantable
  5. https://www.jacc.org/doi/10.1016/j.jacc.2024.02.014

2. European Society of Cardiology – 2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy

  1. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Cardiac-Pacing-and-Cardiac-Resynchronization-Therapy
  2. https://pubmed.ncbi.nlm.nih.gov/34455430/
  3. https://academic.oup.com/eurheartj/article/42/35/3427/6358547
  4. https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2021/08/31/18/37/2021-ESC-Guidelines-on-Cardiac-Pacing-ESC-2021
  5. https://academic.oup.com/eurheartj/article/34/29/2281/401445

Our advantages:

patient2376100
Best practices from USA, EU and Japan
Our answers to your questions are based on the clinical recommendations of countries with the most developed healthcare systems in the field of cardiology in the USA, the EU and Japan.
prescription18648039
Always up-to-date information
On a daily basis, we monitor for you all new scientific research publications in leading scientific journals on medical issues of interest to you.
We monitor all innovations and changes in the field of cardiac disease treatment on a daily basis.
fvfflf7q
Get second opinion
Here you can learn everything that even your doctor may not know about cardiology (if he does not speak English and he does not read 117 leading medical journals on cardiology every month).
1xr4duup
The most comprehensive and up-to-date collection of free cardiology materials
Our website contains the most comprehensive and up-to-date collection of free cardiology materials in your country.
Every 3-5 years, half of the scientific approaches to treatment in the field of cardiology are reviewed as a result of specialized scientific discoveries. With us, you don't have to wait these years to learn about the best ways to treat you and your loved ones.
arrow
Please register in order to receive information regarding possible complications and new approaches to treatment of cardiovascular diseases via email in our Newsletters.
arrow